BREAKTHROUGH: AI reportedly played a major role in helping design Moderna’s personalized skin cancer vaccine, which has now succeeded in a Phase 3 trial.
Moderna and Merck have developed a proprietary AI/ML-powered neoantigen-selection algorithm that helps identify up to 34 tumor mutations to target for each patient.
Moderna then uses those targets to successfully create a personalised mRNA cancer vaccine.